-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Sutro Biopharma, Raises Price Target to $35

Benzinga·04/17/2026 13:18:51
Listen to the news
Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and raises the price target from $23 to $35.